TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Entrada Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$4.82+0.45 (+10.30%)

Close on Oct 19, 2026

Market cap: $203.51M
P/E (TTM): –
Dividend yield: –

Entrada Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Stock-Based Compensation	20	18	13	9.90	2.53	0.33
Deferred Income Taxes	0	0	0	0	–	–
Change in Accounts Payable	-1.80	0.99	-2.81	5.29	-0.72	0.63
Change in Unearned Revenue	-20	-120	140	0	–	–
Operating Cash Flow	-129	-42	140	-94	-51	-26
Capital Expenditures	-1.04	-3.16	-5.61	-2.89	-4.58	-2.32
Purchase of Investments	-142	-438	-407	-222	0	–
Sale & Maturity of Investments	259	413	274	76	0	–
Investing Cash Flow	117	-28	-138	-149	-4.58	-2.32
Financing Cash Flow	0.89	103	21	0.48	307	50
Net Change in Cash	-11	34	22	-242	252	22
Free Cash Flow	-130	-45	134	-97	-55	-28
Income Taxes Paid	1.70	4.62	15	0	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -3767.1%
Net margin: -3537.7%
Return on equity, FY2025: -39.1%

Financial strength

Current ratio: 10.89
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 464.6%

Valuation

P/E ratio: –
Price to sales: 43.43
Price to book: 0.87
Dividend yield: –